Komori
Kissei Pharmaceutical (4547) · RiskMitigated

Environmental Risks of Chemical Substances Used in Research and Manufacturing

First written in FY2016. 18 of 21 entries say "Restated". Latest entry: FY2024.

21entries
9years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY2022-Q3RestatedFY2023-Q1 – FY2024-Q22016: 120162017: 220172018: 320182019: 420192020: 320202021: 120212022: 420222023: 220232024: 12024
Same theme, other companies
Risk of Using Hazardous Chemicals, Biological Materials and Hazardous WasteA theme 20 companies write about · 19 as a headwind · 1 as a tailwind

The whole theme swung hardest in 2021: 1 of 7 companies on the "Worse" side.

1 other company's latest entry also says "Mitigated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 20 companies compared. The sentences above are computed from all 20.
Full recordFilings, disclosures and news, newest first
  1. FY2024MitigatedAnnual report

    「Specifically, we promoted ISO 14001 environmental management systems at our company and group companies, reduced CO2 emissions through the use of 100% renewable electricity, and participated in the Shinshu Green Power Expansion Project, which aims to expand renewable energy generation sources in Nagano Prefecture.」

    Specific measures to address environmental risks have been implemented, including ISO 14001, 100% renewable electricity, and participation in the Shinshu Green Power Expansion Project.
  2. FY2024-Q2RestatedAnnual report

    「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the environmental risks from chemicals used in research and manufacturing.
  3. FY2023-Q3RestatedAnnual report

    「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the environmental risks from chemicals used in research and manufacturing.
  4. FY2023-Q2RestatedAnnual report

    「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the environmental risks from chemicals used in research and manufacturing.
  5. FY2023-Q1RestatedAnnual report

    「During the three-month period ended 30 June, there were no new risks that management recognizes as having the potential to materially affect the financial position, operating results or cash flows of the consolidated companies, and no material changes to the business risks described in the annual securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the environmental risks from chemicals used in research and manufacturing.
  6. FY2022MitigatedAnnual report

    「Specifically, we promoted ISO 14001 environmental management systems at our company and group companies and introduced Shinshu Green Electricity, which is 100% renewable energy.」

    As measures to address environmental risks, we promoted ISO 14001 and introduced 100% renewable energy.
  7. FY2022-Q3RestatedAnnual report

    「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the environmental risks from chemicals used in research and manufacturing.
  8. FY2022-Q2RestatedAnnual report

    「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the environmental risks from chemicals used in research and manufacturing.
  9. FY2021-Q2RestatedAnnual report

    「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the environmental risks from chemicals used in research and manufacturing.
  10. FY2021-Q1RestatedAnnual report

    「No new business or other risks arose during the three months ended 30 June. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the environmental risks from chemicals used in research and manufacturing.
  11. FY2020-Q3RestatedAnnual report

    「No new business or other risks arose during the cumulative third quarter under review. In addition, there have been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the environmental risks from chemicals used in research and manufacturing.
  12. FY2020-Q2RestatedAnnual report

    「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the environmental risks from chemicals used in research and manufacturing.
  13. FY2020-Q1RestatedAnnual report

    「No new business or other risks arose during the first quarter of the current consolidated cumulative period. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the environmental risks from chemicals used in research and manufacturing.
  14. FY2019RestatedAnnual report

    「Some of the chemicals and other substances used in pharmaceutical research and manufacturing may affect the environment. Although each facility implements strict controls and works to protect the environment, if these substances are determined to have caused pollution in surrounding areas, legal action may be taken against the facility, and costs to restore or improve the environment may be incurred, potentially affecting business performance or financial condition.」

    While strictly controlling chemicals, the risks of legal action and environmental restoration costs in the event of pollution have been reconfirmed.
  15. FY2019-Q3RestatedAnnual report

    「No new business or other risks arose during the cumulative third quarter under review. In addition, there have been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the environmental risks from chemicals used in research and manufacturing.
  16. FY2019-Q2RestatedAnnual report

    「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the environmental risks from chemicals used in research and manufacturing.
  17. FY2018RestatedAnnual report

    「Some of the chemicals and other substances used in pharmaceutical research and manufacturing may affect the environment. Although each facility implements strict controls and works to protect the environment, if these substances are determined to have caused pollution in surrounding areas, legal action may be taken against the facility, and costs to restore or improve the environment may be incurred, potentially affecting business performance or financial condition.」

    While strictly controlling chemicals, the risks of legal action and environmental restoration costs in the event of pollution have been reconfirmed.
  18. FY2018-Q3RestatedAnnual report

    「No new business or other risks arose during the cumulative third quarter under review. In addition, there have been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the environmental risks from chemicals used in research and manufacturing.
  19. FY2018-Q2RestatedAnnual report

    「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    It has been reconfirmed that there have been no material changes in the environmental risks from chemicals used in research and manufacturing.
  20. FY2017RestatedAnnual report

    「Although each facility implements strict controls and works to protect the environment, if these substances are determined to have caused pollution in surrounding areas, legal action may be taken against the facility, and costs to restore or improve the environment may be incurred, potentially affecting business performance or financial condition.」

    While implementing strict controls over chemicals, the risks of legal action and environmental restoration costs in the event of pollution have been reconfirmed.
  21. FY2016First statedAnnual report

    「Some of the chemicals and other substances used in pharmaceutical research and manufacturing may affect the environment. Although each facility implements strict controls and works to protect the environment, if these substances are determined to have caused pollution in surrounding areas, legal action may be taken against the facility, and costs to restore or improve the environment may be incurred, potentially affecting business performance or financial condition.」

    While implementing strict controls, the risk of environmental pollution, legal action, and restoration costs is identified.
Moved together

"Enhancing and Strengthening a Product Portfolio with Distinctive Features and Competitive Advantages" moved the same way as this thread, in the same document, in 2 of its 21 moves.

222222★123456
  1. ★This thread
  2. 1Enhancing and Strengthening a Product Portfolio with Distinctive Features and Competitive Advantages2×
  3. 2Efficient Advancement of Clinical Trials for Development Programs and Early Approval2×
  4. 3Promoting overseas expansion and stabilizing the overseas earnings base2×
  5. 4Improving Operating Profit Margin and Profitability2×
  6. 5Stable dividends and profit allocation in line with earnings2×
  7. 6Strengthening Governance to Enhance Corporate Value and Achieve Sustainable Growth2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Kissei Pharmaceutical's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Environmental Risks of Chemical Substances Used in Research and Manufacturing | KISSEI PHARMACEUTICAL CO.,LTD. (4547) | Komori